Dry-herb cannabis vaping is lower-risk than smoking burnt plant material, but 20 g/week is still heavy daily THC exposure, not a “healthy smoking” substitute. It avoids nicotine and much combustion toxicant exposure, so it is not comparable to a pack/day cigarette habit for lung cancer, COPD, or all-cause mortality. The distinct risk is THC burden: dependence/withdrawal, sleep disruption, cognition/executive-function drag, anxiety/psychosis vulnerability, cannabinoid hyperemesis, impaired driving, and possible cardiovascular triggering. With Lp(a) 838.6 mg/L, unknown BP burden, recent smoking-linked WBC noise, and platelet/thrombotic context, daily high-dose cannabis would be a bad risk tradeoff during the current cleanup/imaging phase.
cannabis · dry-herb-vape · thc · cardiovascular-risk · cognition · sleep · addiction
A dry-herb vape is a harm-reduction route compared with burning joints, but it does not make heavy daily cannabis benign. At 20 g/week, use averages 2.86 g/day. If flower is 15-25% THC, the raw plant contains roughly 430-714 mg THC/day before delivery losses. That is far beyond “occasional” use and lands in the guideline-defined high-risk pattern: daily/near-daily, high cumulative exposure.
Practical comparison:
| Exposure | Best current read |
|---|---|
| Pack/day cigarettes | Clearly worse for proven mortality, lung cancer, COPD, coronary disease, stroke, peripheral disease, and multi-organ cancer risk. Combustion + nicotine + thousands of toxicants; lifelong continuation costs roughly a decade of life in classic cohort data. |
| 20 g/week dry-herb cannabis vape | Probably much lower cancer/COPD/all-cause-mortality burden than pack/day cigarettes, especially without tobacco or combustion. But it is not “safe”: the main risks are THC-dose, dependence, sleep/cognition/mental-health effects, impaired driving/injury, cannabinoid hyperemesis, and cardiovascular triggering. |
Bottom line: not as bad as a pack/day cigarette habit, but bad enough that it should not be treated as a harmless substitute. For this profile, daily high-dose THC would be a risk multiplier and a data-confounder.
| Branch | Why daily cannabis vaping is costly here |
|---|---|
| Lp(a) / ASCVD | Cannabis acutely raises heart rate and can raise BP; AHA notes few cardiovascular benefits and multiple concerns. A 2024 BRFSS analysis found daily use associated with higher odds of MI, stroke, and composite cardiovascular outcomes even among never-tobacco smokers. This is observational, not proof like tobacco, but the direction is bad when Lp(a) is already extreme. |
| BP / autonomic signal | BP is still a major blind spot. THC can add tachycardia, orthostatic effects, anxiety/panic, and sleep/autonomic noise, making the 7-day BP and Apple Watch signals harder to interpret. |
| Inflammation / WBC / platelets | Vaping avoids much smoke toxicant exposure, but heavy THC use can still alter sleep, stress, activity, and adherence. It would muddy whether final clean-month WBC/platelets/fibrinogen changes reflect smoking cessation, gut changes, or cannabis effects. |
| Sleep / cognition | Cannabis may feel sleep-helpful short term, but evidence for durable sleep benefit is weak; withdrawal commonly causes insomnia, irritability, anxiety, appetite change, and depressed mood. Heavy use can create a sleep-dependence loop. |
| Gut | Chronic heavy use is the exposure pattern behind cannabinoid hyperemesis syndrome: cyclic nausea/vomiting, abdominal pain, hot-shower relief, and resolution only with abstinence. This would be especially unhelpful with existing bloating/GI monitoring. |
| Function / safety | Acute impairment affects memory, reaction time, coordination, judgment, and driving. Daily use also raises the chance that “baseline” mood, motivation, exercise, appetite, and learning are actually drug-state dependent. |
Cigarettes are mainly a combustion/nicotine vascular-cancer machine. Cannabis is mainly a THC-exposure and impairment/dependence problem, with cardiovascular uncertainty layered on top.
| Risk domain | Cigarettes pack/day | Dry-herb cannabis 20 g/week |
|---|---|---|
| Mortality evidence | Strong, causal, dose-response; current smoking roughly doubles all-cause mortality in many cohorts and strongly raises CVD/cancer deaths. | Much weaker and less settled for all-cause mortality; confounding by tobacco and variable dose are major problems. |
| Lung cancer / COPD | Strong causal link. | Smoked cannabis causes bronchitis symptoms; COPD/lung-cancer links are much less clear. Dry-herb vaping likely lowers combustion exposure further, but long-term data are thin. |
| Cardiovascular | Strong causal risk: coronary disease and stroke about 2-4x higher than never-smokers in CDC summaries. | Acute sympathetic/hemodynamic effects are real; observational data link heavier use to MI/stroke. Causality and long-term magnitude are less certain, but high-risk profiles should not ignore it. |
| Addiction | Nicotine dependence is severe and fast-reinforcing. | Cannabis use disorder is common with frequent use; withdrawal meta-analysis found ~47% prevalence among regular/dependent users, higher with daily use. |
| Mental health / cognition | Nicotine withdrawal, anxiety, and vascular cognitive risk; not typically psychosis-provoking. | Daily/high-potency THC has clearer links to psychosis risk, anxiety/panic, memory/executive-function impairment, and motivational/function drag in susceptible users. |
| GI syndrome | Not a CHS pattern. | Heavy chronic cannabinoid exposure can cause cannabinoid hyperemesis syndrome. |
For the current health plan: do not add daily cannabis during the 30-day experiment, final labs, BP profiling, or cardiac-imaging phase. It would make the most important open questions harder to interpret.
If cannabis becomes a deliberate experiment later, make it a separate logged exposure with a pre-set ceiling: non-daily, low-THC/high-CBD, dry-herb only, no driving, and stop if sleep, HR/BP, anxiety, appetite, GI symptoms, or exercise consistency worsens.